Brokerages forecast that Catalent Inc (NYSE:CTLT) will report earnings per share of $0.34 for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Catalent’s earnings, with estimates ranging from $0.30 to $0.36. Catalent posted earnings of $0.27 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 25.9%. The business is scheduled to announce its next earnings results on Monday, February 5th.
On average, analysts expect that Catalent will report full year earnings of $1.60 per share for the current fiscal year, with EPS estimates ranging from $1.53 to $1.70. For the next fiscal year, analysts forecast that the business will post earnings of $1.82 per share, with EPS estimates ranging from $1.73 to $1.94. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Catalent.
Catalent (NYSE:CTLT) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.01. The business had revenue of $543.90 million during the quarter, compared to analyst estimates of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The business’s revenue was up 23.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.16 earnings per share.
Shares of Catalent (NYSE CTLT) traded up $0.05 during trading on Tuesday, reaching $41.51. The company had a trading volume of 360,178 shares, compared to its average volume of 913,073. The stock has a market capitalization of $5,508.35, a price-to-earnings ratio of 47.71, a price-to-earnings-growth ratio of 2.66 and a beta of 1.41. Catalent has a 52 week low of $25.51 and a 52 week high of $43.39. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01.
In related news, Director Uwe Roehrhoff acquired 7,500 shares of Catalent stock in a transaction dated Tuesday, November 21st. The shares were acquired at an average cost of $39.22 per share, for a total transaction of $294,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John R. Chiminski sold 181,458 shares of the stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Zions Bancorporation acquired a new stake in Catalent in the third quarter valued at $100,000. Acrospire Investment Management LLC grew its holdings in shares of Catalent by 72.2% during the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after purchasing an additional 1,300 shares during the last quarter. Quantbot Technologies LP grew its holdings in shares of Catalent by 110.7% during the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after purchasing an additional 1,804 shares during the last quarter. Fortaleza Asset Management Inc. purchased a new position in shares of Catalent during the third quarter worth about $164,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Catalent by 12.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after purchasing an additional 559 shares during the last quarter. Institutional investors and hedge funds own 99.37% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://weekherald.com/2017/12/26/0-34-eps-expected-for-catalent-inc-ctlt-this-quarter-2.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.